title: Increased periocular pigmentation with ocular hypotensive lipid use in African Americans.
abstract: OBJECTIVE
  To report increased eyelid pigmentation as an adverse side effect associated with topical ocular hypotensive lipids in African Americans.
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  Two African-American patients with open-angle glaucoma are described in whom increased eyelid pigmentation developed 1 month to 5 months after beginning treatment with either latanoprost or bimatoprost.
  
  
  RESULTS
  Latanoprost was discontinued in an African-American patient, and pigmentation gradually diminished by 3 months after cessation of latanoprost. Increased eyelid pigmentation and increased eyelash length were noted in another African-American patient after just 4 weeks on bimatoprost.
  
  
  CONCLUSIONS
  An increase in eyelid pigmentation and eyelash growth is a possible complication of topical ocular hypotensive lipid therapy, even in African-American patients. The changes seems to present earlier after bimatoprost treatment then after latanoprost treatment. Cessation of these medications may lead to loss of induced pigmentation.
authors.affiliation: Duke University Eye Center, Durham, North Carolina 27710, USA. hernd012@mc.duke.edu
authors.forename: Leon W
authors.initials: LW
authors.lastname: Herndon
authors.lastname: Robert D  Williams
authors.forename: Martin
authors.initials: M
authors.lastname: Wand
authors.forename: Sanjay
authors.initials: S
authors.lastname: Asrani
mesh_terms: D000577:Amides; D000959:Antihypertensive Agents / Q000009:adverse effects*; D000069580:Bimatoprost; D044383:Black People; D003008:Cloprostenol / Q000031:analogs & derivatives; D005141:Eyelid Diseases / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000208:ethnology*; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced* / Q000473:pathology; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008055:Lipids / Q000009:adverse effects; D008875:Middle Aged; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects; D012880:Skin Pigmentation / Q000187:drug effects*; D001741:Black or African American
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost